eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

5/2016
vol. 8
 
Share:
Share:
abstract:
Original paper

The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy

Michelle I. Echevarria
,
Arash O. Naghavi
,
Puja S. Venkat
,
Yazan A. Abuodeh
,
Carlos Chevere
,
Kosj Yamoah

J Contemp Brachytherapy 2016; 8, 5: 386–390
Online publish date: 2016/11/02
View full text Get citation
 
Purpose: Low-dose-rate (LDR) brachytherapy has been established as an effective and safe treatment option for men with low and intermediate risk prostate cancer. In this retrospective analysis, we sought to study the effect of body mass index (BMI) on post-implant dosimetric quality.

Material and methods: After institutional approval, records of patients with non-metastatic prostate cancer treated in Puerto Rico with LDR brachytherapy during 2008-2013 were reviewed. All patients were implanted with 125I seeds to a prescription dose of 145 Gy. Computed tomography (CT) based dosimetry was performed 1 month after implant. Patients with at least 1 year of prostate-specific antigen (PSA) follow-up were included. Factors predictive of adequate D90 coverage (≥ 140 Gy) were compared via the Pearson χ2 or Wilcoxon rank-sum test as appropriate.

Results: One-hundred and four patients were included in this study, with 53 (51%) patients having a D90 ≥ 140 Gy. The only factor associated with a dosimetric coverage detriment (D90 < 140 Gy) was BMI ≥ 25 kg/m2 (p = 0.03). Prostate volume (p = 0.26), initial PSA (p = 0.236), age (p = 0.49), hormone use (p = 0.93), percent of cores positive (p = 0.95), risk group (p = 0.24), tumor stage (p = 0.66), and Gleason score (p = 0.61) did not predict D90.

Conclusions: In this study we show that BMI is a significant pre-implant predictor of D90 (< 140 Gy vs. ≥ 140 Gy). Although other studies have reported that prostate volume also affects D90, our study did not find this correlation to be statistically significant, likely because all of our patients had a prostate volume < 50 cc. Our study suggests that in patients with higher BMI values, more rigorous peri-implant dosimetric parameters may need to be applied in order to achieve a target D90 > 140 Gy.
keywords:

BMI, low-dose-rate brachytherapy, prostate cancer, seeds

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.